3 Things to Watch With Spectrum Pharmaceuticals

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Spectrum Pharmaceuticals (Nasdaq: SPPI  ) is a biopharmaceutical company focused on developing treatments with an oncological or hematological focus.

Today, let's look at three things investors should be watching regarding Spectrum Pharmaceuticals, as they will provide us better insight into the company.

1. Fusilev sales and pricing
Without question, the near-term catalyst for Spectrum Pharmaceuticals is the growth of its lead drug, Fusilev. Fusilev is approved as a combination therapy in patients being treated for advanced colorectal cancer, and is administered to treat the nasty side effects of methotrexate.

In Spectrum's most recent quarter, Fusilev sales shot up 67% to $56.6 million from its year-earlier total of $33.9 million. Sales of the drug have consistently increased since its debut, and it remains the primary growth driver, accounting for 82.4% of total revenue.

However, things aren't always what they appear on the surface. It's clear from regulatory filings -- despite Spectrum's unwillingness to breakdown its gross Fusilev sales -- that it's doling out big discounts to physicians in order to encourage them to keep prescribing Fusilev instead of switching to the cheaper generic, leucovorin, which is made by generic giant Teva Pharmaceuticals (NYSE: TEVA  ) , among others. According to monthly data compiled by research firm Wolters Kluwer, Fusilev sales could have been as high as $97 million this past quarter, but came in at a discount of 41% to that figure. If Spectrum is going to protect its brand name, keep shareholders happy, and grow sales volume, it's going to need to walk on water with the pricing of its combination therapy Fusilev.

2. Zevalin sales and the Allos acquisition
On the other side of the coin, Zevalin sales have been stagnant for years. The drug, which is approved to treat follicular lymphoma, has suffered from a competitive sales environment and an unpleasant amount of steps that needed to be undertaken to prescribe the drug. One of those steps fell by the wayside late last year when the Food and Drug Administration lifted the requirement that a bioscan be done on patients prior to prescribing Zevalin. This could be the impetus that finally moves sales higher.

Also working in Spectrum's favor could be its purchase of Allos Therapeutics (Nasdaq: ALTH  ) for $1.82 per share (plus an additional $0.11 if its key drug is approved in the European Union), which is set to close this week. Allos' lead drug, Folotyn, treats patients with relapsed or refractory peripheral T-cell lymphoma (PCTL) and is a drug that would be prescribed by the same doctors prescribing Zevalin. The two drugs aren't competitors to each other, and Spectrum is forecasting significant synergies from the combination.

As usual, investors should also be keeping their eyes on Folotyn's sales and the sizable amount of competition that threatens to eat into its existing sales. As my Foolish colleague Keith Speights noted last week, Folotyn volume actually decreased 10% in the first half of 2012 and was aided only by a 5% increase in price. On top of that, there are three notable PCTL drugs already carving into Folotyn's piece of the pie, including Baxter International's generic drug Cytoxan, Celgene's Istodax, and Teva's generic drug, Vincristine.

3. Spectrum's remaining pipeline
According to Spectrum's product pipeline, it's currently advancing 14 drug candidates. Even if many of these drugs fail, with the company profitable from just Fusilev, Zevalin, and with the addition of Folotyn, there's a good chance that at least a few of these experimental drugs could become winners.

Belinostat is one such drug that investors should be keeping an eye on. The drug, which is targeted at treating PCTL and non-small cell lung cancer (NSCLC), has shown efficacy and tolerability in reducing cancer cell proliferation in various phase 1 and 2 clinical trials with minimal side effects and marrow toxicity. Lucanthone, which is still in early clinical trials, is also worth keeping an eye on. It's being targeted at treating brain metastasis tied to NSCLC by crossing the blood brain barrier.

Of course, there will be losers as well. Just prior to announcing the buyout of Allos Therapeutics, Spectrum noted unfavorable results in two phase 3 clinical trials for its bladder cancer drug apaziquone, which is developed with its marketing partner, Allergan (NYSE: AGN  ) . It's unlikely apaziquone will be shelved, but an FDA-approval appears unlikely as of now.

Foolish roundup
Now that you know what to watch for, it should be easier to analyze Spectrum Pharmaceuticals' successes and pitfalls in the future, and hopefully you'll gain a competitive investing edge.

If you're still craving even more info on Spectrum Pharmaceuticals, I would recommend adding the stock to your free and personalized watchlist so you can keep up on all of the latest news with the company.

Just as Spectrum Pharmaceuticals is seeking to uncover and commercialize the next disruptive technology in the biotechnology sector, our analysts are seeking out the next disruptive technology that could revolutionize the tech sector. In our latest special report, you can find out the identity of three stocks they feel are set to lead the next industrial revolution. Click here and get this special report, for free, for a limited time!

Fool contributor Sean Williams has no material interest in any of the companies mentioned in this article. You can follow him on Motley Fool CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy that's the perfect therapy for the transparency blues.

Read/Post Comments (1) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 05, 2012, at 1:29 AM, idahithat wrote:

    "Sean Williams has no material interest" and apparently little research interest in writing about SPPI. Omissions and mistakes abound.

    First, and you are somewhat blameless as it was only recently announced, the Allos deal is done. The final 10% of un-tendered shares will be cancelled and replaced with a right to 1.82/share on 9/5/12. Its over. Hmmm so, the FTC was to blame for the delay, not some nefarious issues between ALTH and SPPI. Go figure. Congrats SPPI.

    But what you should have known if you didn't simply slap this article together was, the $0.11 up payment is dead long ago, EU failed to approve at this time.

    But on to other more important issues, the far from clear Wolters Kluwer data - If discounts were to blame for the WK vrs. SPPI data difference, when SPPI actually reported it's torrid & record smashing " $56.6 million ...[quarterly] sales of FUSILEV net of estimates for promotional, price and other adjustments..."). In fact the supposed 41% discount as you put it ( $39.7M) shows nowhere on SPPI's filings. Heres a clue - the WK estimates were WRONG. WK overestimated the sales, then reports banging the over estimate was used to finagle a Fusilev shortcoming!

    Now SPPIs CEO has publicly called out thestreet bomb hurler ( who has incidently been derisive of SPPI since $2 , now > $12 and recently $17 ) as politely as possible given the circumstances ( SPPI's Aug 30 presentation is a Must Listen ). I paraphrase ' No fusilev discounts, instead ASP increases, and projecting a $300 MILLION revenue range for SPPI this year, after $197 million last year. That, my author, is what counts !

    on to other matters;

    Not only are Folotyn and Zevalin non-competitors and prescribed by many of the same physicians, but a main side effect of Foloyton (Redness and sores of the mucous membrane) is counteracted by SPPI's Fusilev ! Talk about win win. Expect to see folotyn sales respond to the excellant sales team of SPPI.

    Although you could have efforted to make this article foolproof, apparently it's still shorted of damn foolproof.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2005375, ~/Articles/ArticleHandler.aspx, 10/25/2016 1:29:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,179.79 -43.24 -0.24%
S&P 500 2,145.12 -6.21 -0.29%
NASD 5,282.26 -27.57 -0.52%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 1:12 PM
SPPI $3.70 Down -0.13 -3.39%
Spectrum Pharmaceu… CAPS Rating: ***
AGN.DL $0.00 Down +0.00 +0.00%
Allergan CAPS Rating: ****
ALTH.DL $0.00 Down +0.00 +0.00%
Allos Therapeutics… CAPS Rating: ***
TEVA $43.99 Up +0.49 +1.13%
Teva Pharmaceutica… CAPS Rating: ****